Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for urinary incontinence due to overactive bladder in adolescents
NL-OMON42096Phase 3Active, not recruiting
- Sponsor
- Allergan
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in overactive bladder (OAB) (3 arms), sponsored by Allergan. Primary endpoint: Number of daytime urinary incontinence episodes. Started May 2014; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON42096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42096.